Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 3

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
 Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Products and services revenue$148,019 $151,559 $430,999 $445,554 License and royalty revenue983 95 45,794 210 Revenue149,002 151,654 476,793 445,764 Cost of products and services revenue48,695 45,261 145,957 142,237 Gross profit100,307 106,393 330,836 303,527 Operating expenses:Research and development57,194 66,174 182,663 197,730 Selling, general and administrative75,355 81,704 239,517 250,517 Gain on settlement— — (49,900)— Total operating expenses132,549 147,878 372,280 448,247 Loss from operations(32,242)(41,485)(41,444)(144,720)Other income (expense):Interest income5,199 4,971 13,156 14,422 Interest expense3 (2)— (4)Other income (expense), net(1,165)2,078 3,574 982 Total other income4,037 7,047 16,730 15,400 Loss before provision for income taxes(28,205)(34,438)(24,714)(129,320)(Benefit from) provision for income taxes(733)1,315 2,578 4,279 Net loss$(27,472)$(35,753)$(27,292)$(133,599)Net loss per share, basic and diluted$(0.22)$(0.30)$(0.22)$(1.11)Weighted-average shares used to compute net loss per share, basic and diluted125,502,291 120,733,030 123,965,205 120,067,168 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

10x Genomics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In thousands)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024